2019

23-25 October

 

Keynote speakers

Leading experts in their fields

1250 Participants

In 2017 edition

About Lisbon Addictions 2019

Lisbon Addictions 2019, the third European Conference on Addictive Behaviours and Dependencies, is a multidisciplinary conference that provides a forum for networking across the addictions.

Over 1 200 participants from 70 countries attended Lisbon Addictions 2017. The conference sold out several months before the event. See presentations and posters.

Following the renewed success of the conference initiative, the organisers have decided to launch Lisbon Addictions 2019 (#LxAddictions19), which will take place in the Lisbon Congress Centre from 23–25 October 2019.

Once again, the event will be jointly organised by the Portuguese General Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), the journal Addiction/Society for the Study of Addiction, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the International Society of Addiction Journal Editors (ISAJE).

The overarching theme for 2019 is 'The future of addictions: new frontiers for policy, practice and science'. The conference will therefore showcase cutting-edge research to help characterise, understand and respond to addiction and addictive behaviours

#LxAddictions19 will provide opportunities for early-stage reseachers to enhance their careers. The Programme and Organising Committees have therefore planned to hold dedicated showcase sessions, developed a new concept for poster sessions and will further promote networking activities and mentoring to meet the needs of these participants.

Key dates

28 February 2019: Deadline for early-bird registration fee (EUR 400)
31 May 2019: Notification to authors
29 June 2019: Deadline for late-breaking abstracts
30 June 2019: Deadline for regular registration (EUR 500)
1 July–25 October 2019: Late registration (online and on-site – EUR 600)

Programme

Under the overarching theme ‘The future of addictions: new frontiers for policy, practice and science’, potential contributors are invited to submit abstracts for the following main areas:

  • Futures: identifying and meeting emerging needs; prediction, preparedness, innovations and new challenges;
  • Better practice: improving how we respond; supporting the development and implementation of more effective prevention, treatment, and harm reduction interventions;
  • Better science: aetiology, basic science, neuroscience and pre-clinical studies;
  • Better methods: epidemiology, monitoring estimates and models;
  • Better society: overcoming barriers, effective policies, regulations and laws; culture and context.

FuturiZe

The EC co-funded project FuturiZe (FZ) will collaborate with the organisers of Lisbon Addictions 2019 by developing networking activities and a series of interactive debates which focus on key future scenarios in the field of drugs and behavioural addictions. The scenarios will be chosen and developed through a participatory process with a wide variety of stakeholders. The FZ debates will be open to all conference participants and introduced in each case by prominent thinkers from different backgrounds and perspectives. The project will also provide bursaries for around 120 multi-sectoral professionals who would otherwise not be able to attend the event.

The FuturiZe future scenarios consultation survey is the first step in a participatory process to develop a set of scenarios and a corresponding series of interactive debates at the Lisbon Addictions 2019 conference.

This survey is a scoping exercise to gather expert opinion and insight into future issues in the area of addictions. Read more >>

Side events and networking

#LxAddictions19 will again provide a unique networking opportunity for researchers, practitioners and policy experts across countries and disciplines, addressing new challenges and covering developing fields. In the margins of the conference various major events will take place.

To promote networking, conference rooms will be available for side events. If interested, please contact us at: lisbonaddictions2019@abreu.pt

Call for abstracts

Submission of abstracts was closed 4 February 2019.

Applicants will be informed if their contribution has been accepted for inclusion in the conference programme by 31 May 2019.

In June a limited number of late-breaking abstracts may be accepted as posters.

Registration

Online registration is now open. Places for non-presenters will be allocated on a first come, first served basis. All persons intending to attend the conference must register and pay the applicable registration fee, including paper and poster presenters, discussants and chairs.

The conference registration fee is EUR 400 for early bird registration (until 28 February), EUR 500 (until 30 June) and EUR 600 for those registering after this date.

Register now >>

 

Students’ fee

In order to encourage participation in Lisbon Addictions 2019 for those not in full time employment, a limited number of places with a reduced fee (EUR 250) have been made available (until the 28th February 2019) on a first come, first served basis. Applicants should be students registered in a relevant academic programme and not in full time employment. They should fill in the registration form and tick the 'Special students’ fee' box and upload or send a formal confirmation from their University to lisbonaddictions2019@abreu.pt.

Please note that those registering with the special students' fee will not be eligible for selection under the FuturiZe project. For more information about the FuturiZe project, visit www.lx-futurize.eu or contact futurize@clinic.cat.

 

Organisers and partners

Organisers

Planets Addiction SAS
  • Judith Aldridge (Senior Lecturer, School of Law, University of Manchester, UK)
  • Alexander Baldacchino (Professor of Medicine, Psychiatry and Addictions, University of St Andrews, UK)
  • Henri Bergeron (Chair in Health Studies, Sciences Po Paris, France)
  • Virginia Berridge (Professor of History and Director, Centre for History in Public Health, London School of Hygiene and Tropical Medicine, UK)
  • Kim Bloomfield (Professor, Center for Alcohol and Drug Research, Aarhus University, Denmark)
  • Henrietta Bowden-Jones (Consultant Psychiatrist. Founder and Director, National Problem Gambling Clinic, UK)
  • Jørgen G. Bramness (Senior researcher, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norwegian Centre of Dual Diagnosis)
  • Anne Line Bretteville-Jensen (Research Director, Norwegian Institute for Alcohol and Drug Research (SIRUS), Norway)
  • Angelina Brotherhood (Public Health Researcher, Liverpool John Moores University, UK)
  • Rachel Btaiche (Focal Person, National Observatory on Drugs and Drug Addiction, Ministry of Public Health, Lebanon)
  • Gerhard Bühringer (Chair of Addiction Research, Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Germany)
  • Catherine Comiskey (Head of School of Nursing and Midwifery, Trinity College, Ireland)
  • Ornella Corazza (Reader in Substance Addictions and Behaviours, University of Hertfordshire, Hatfield, UK)
  • Paul Dargan (Consultant Physician and Clinical Toxicologist, Guy's and St Thomas' NHS Foundation Trust, and Reader in Toxicology, King’s College London, UK)
  • Marina Davoli (Head, Department of Epidemiology, National Agency for Health Services, Italy)
  • Louisa Degenhardt (Professor, National Drug and Alcohol Research Centre (NDARC), Australia)
  • Zsolt Demetrovics (ELTE Eötvös Loránd University, Budapest, Hungary)
  • Cuneyt Evren (Associate Professor of Psychiatry, Head of Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Istanbul, Turkey)
  • Fernando Rodríguez de Fonseca (Fundación IMABIS, Hosp. Univ. Carlos Haya de Málaga, Spain)
  • Fabrizio Faggiano (Professor of Public Health at the Department of Translational Medicine of the University of the Piemonte Orientale, Italy)
  • Michael Farrell (Director, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Australia)
  • Gabriele Fischer (Medical Director of the Addiction Clinic at the Medical University Vienna, Austria)
  • Henk Garretsen (Professor, Director Tranzo, Scientific Centre for Care and Welfare, Tilburg University, The Netherlands)
  • Eilish Gilvarry (President of the Society for the Study of Addiction, Honorary Professor of Addiction Psychiatry, Newcastle University, UK)
  • Manuela Grazina (Professor, Faculty of Medicine; Researcher and Head of Laboratory of Biochemical Genetics, Center for Neuroscience and Cell Biology; University of Coimbra, Portugal)
  • Jason Grebely (Associate Professor, The Kirby Institute, UNSW Sydney, Australia)
  • Antoni Gual (Director of the Addictions Unit, Hospital Clínic Barcelona, Spain)
  • Wayne Hall (Professor, Director and Inaugural Chair, Centre for Youth Substance Abuse Research, The University of Queensland, Australia)
  • Matthew Hickman (School of Social and Community Medicine, University of Bristol, UK)
  • Susana Jiménez-Murcia (Head of Pathological Gambling Unit, Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain)
  • Beau Kilmer (Co-director and senior policy researcher, RAND Drug Policy Research Center; Professor, Pardee RAND Graduate School, USA)
  • Dirk Korf (Professor, Bonger Institute of Criminology, University of Amsterdam, The Netherlands)
  • Krzysztof Krajewski (Chair of Criminology, Jagiellonian University, Poland)
  • Ludwig Kraus (Director, IFT Institut für Therapieforschung, Munich, Germany)
  • Håkan Leifman (Director, Swedish Council for Information on Alcohol and Other Drugs (CAN), Sweden)
  • Henrique Lopes (President of the Ibero-latin-american Scientific Society for Gambling Research, Chair of CEIA Research Center, researcher at Public Healthcare Unit of Catholic University - ICS)
  • Pia Mäkelä (Head of Alcohol and Drugs Unit, National Institute for Health and Welfare, Finland)
  • Meni Malliori (Associate Professor of Psychiatry, Medical School, National & Kapodistrian University of Athens, Greece)
  • Angela Me (Chief of the Research and and Trend Analysis Branch, United Nations Office on Drugs and Crime)
  • Emília Nunes (Professor, Director of the National Programme for Prevention of Smoking and Tobacco Control, General-Directorate of Health, Portugal)
  • Letizia Paoli (Professor, Leuven Institute of Criminology, University of Leuven, Faculty of Law, Belgium)
  • Amy Porath (Director, Research and Policy, Canadian Centre on Substance Abuse, Canada)
  • Jürgen Rehm (Director, Social and Epidemiological Research (SER) Department, Centre for Addiction and Mental Health, Toronto, Canada)
  • Xavier Majó i Roca (Office of Drug Addiction, Public Health Agency of Catalonia, Spain)
  • Tim Rhodes (Professor of Public Health Sociology, London School of Hygiene and Tropical Medicine (UK)/University of New South Wales (Australia))
  • Zila M. Sanchez (Professor of Epidemiology, Preventive Medicine Department, Universidade Federal de São Paulo, Brazil)
  • Emanuele Scafato (Director of Population’s Health and Health Determinants Unit in the National Centre for Epidemiology, Surveillance and Health Promotion-CNESPS at the Istituto Superiore di Sanità, Italy)
  • Eberhard Schatz (Coordinator CORRELATION network)
  • Janusz Sieroslawski (Institute of Psychiatry and Neurology, Poland)
  • Zili Sloboda (President, Applied Prevention Science, Inc., USA)
  • Rainer Spanagel (Professor of Pharmacology & Toxicology, Head of the Institute of Psychopharmacology, University of Heidelberg, Germany)
  • Kerstin Stenius (Assistant Professor, Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; Alcohol and Drugs unit, National Institute for Health and Welfare, Finland; and Nordic Centre for Welfare and Social Issues, Finland)
  • John Strang (Professor, Head of the Addictions Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, UK)
  • Harry Sumnall (Professor, Centre for Public Health, Liverpool John Moores University, UK)
  • Margriet Van Laar (Head of the Department Drug Monitoring, Trimbos Institute, The Netherlands)
  • Julian Vicente (Lead scientist, epidemiology, EMCDDA)
  • Graça Vilar (Director of the Planning and Intervention Department of SICAD, Master in forensic medicine and forensic sciences, Graduate Assistant of Psychiatry Hospital, Portugal)
  • Chris Wilkins (Senior Researcher, Drugs Team Leader, SHORE & Whariki Research Centre, College of Health, Massey University, Auckland, New Zealand)

Co-chairs: Manuel Cardoso (SICAD), Paul Griffiths (EMCDDA)

  • John Marsden (Addiction/SSA)
  • Julia Sinclair (Addiction/SSA)
  • Michal Miovsky (ISAJE)
  • Richard Pates (ISAJE)
  • Ana Sofia Santos (SICAD)
  • Ana Castela Rodrigues (SICAD)
  • Maria Moreira (EMCDDA)
  • Klaudia Palczak (EMCDDA)

Co-chairs: Ana Sofia Santos (SICAD), Maria Moreira (EMCDDA)

  • Ana Castela Rodrigues (SICAD)
  • Sonia Ferreira (SICAD)
  • Filipa Cunha (SICAD)
  • Carla Cachola (SICAD)
  • Klaudia Palczak (EMCDDA)
  • Marie-Christine Ashby (EMCDDA)
  • Silke Vitt (EMCDDA)
  • Ângela Antunes (EMCDDA)
  • Renate De Neve (EMCDDA)